Targeted Inflammation During Oncolytic Virus Therapy Severely Compromises Tumor Blood Flow

This publication has 43 references indexed in Scilit:

• Triple-Targeted Oncolytic Adenoviruses Featuring the Cox2 Promoter, E1A Transcomplementation, and Serotype Chimerism for Enhanced Selectivity for Ovarian Cancer Cells
  Molecular Therapy, 2006
• Recent progress in the battle between oncolytic viruses and tumours
  Nature Reviews Cancer, 2005
• Recombinant Adenovirus Vectors Activate the Alternative Complement Pathway, Leading to the Binding of Human Complement Protein C3 Independent of Anti-Ad Antibodies
  Molecular Therapy, 2004
• Oncolytic viruses for the treatment of cancer: current strategies and clinical trials
  Drug Discovery Today, 2004
• VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents
  Cancer Cell, 2003
• Getting oncolytic virus therapies off the ground
  Cancer Cell, 2003
• Pre-Existent Adenovirus Antibody Inhibits Systemic Toxicity and Antitumor Activity of CN706 in the Nude Mouse LNCaP Xenograft Model: Implications and Proposals for Human Therapy
  Human Gene Therapy, 2000
• Complement Depletion Facilitates the Infection of Multiple Brain Tumors by an Intravascular, Replication-Conditional Herpes Simplex Virus Mutant
  Journal of Virology, 2000
• Brief Report: Liver Bypass Significantly Increases the Transduction Efficiency of Recombinant Adenoviral Vectors in the Lung, Intestine, and Kidney
  Human Gene Therapy, 2000
• Oncolytic viruses as novel anticancer agents: turning one scourge against another
  Expert Opinion on Investigational Drugs, 2000